Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

Journal of Hepatology

Volumn 66, Issue 1, 2017, Pages 39-47

  Pol, Stanislas ^a   Bourliere, Marc ^b   Lucier, Sandy ^c   Hezode, Christophe ^d   Dorival, Céline ^c   Larrey, Dominique ^e   Bronowicki, Jean Pierre ^f   Ledinghen, Victor D E ^g,h   Zoulim, Fabien ⁱ   Tran, Albert ^j   Metivier, Sophie ^k   Zarski, Jean Pierre ^l   Samuel, Didier ^m   Guyader, Dominique ⁿ   Marcellin, Patrick ^o   Minello, Anne ^p   Alric, Laurent ^q   Thabut, Dominique ^r   Chazouilleres, Olivier ^s   Riachi, Ghassan ^t   Bourcier, Valérie ^u   Mathurin, Philippe ^v   Loustaud Ratti, Véronique ^w   D'Alteroche, Louis ^x   Fouchard Hubert, Isabelle ^y   Habersetzer, François ^z   Causse, Xavier ^aa   Geist, Claire ^ab   Rosa, Isabelle ^ac   Gournay, Jérôme ^ad   Saillard, Eric ^ae   Billaud, Eric ^af   Petrov Sanchez, Ventzislava ^ag   Diallo, Alpha ^ah   Fontaine, Hélène ^a   Carrat, Fabrice ^c,ai   more..

^a INSTITUT PASTEUR   (France)

^b HÔPITAL SAINT JOSEPH   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e HÔPITAL SAINT ELOI   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h INSERM   (France)

ⁱ CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^j UNIVERSITY HOSPITAL OF NICE   (France)

^k CHU PURPAN   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ UNIVERSITÉ DE RENNES 1   (France)

^o BEAUJON HOSPITAL   (France)

^p DIJON UNIVERSITY HOSPITAL   (France)

^q UMR 152 IRD Universite Paul Sabatier   (France)

^r PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^s ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^t HÔPITAL CHARLES NICOLLE   (France)

^u UNIVERSITÉ PARIS 13   (France)

^v Center Hospitalier et Universitaire   (France)

^w UNIVERSITY OF LIMOGES   (France)

^x SERVICE DE DERMATOLOGIE   (France)

^y ANGERS UNIVERSITY HOSPITAL   (France)

^z UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^aa CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^ab Centre Hospitalier Ré gional   (France)

^ac CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^ad HÔTEL DIEU   (France)

^ae CHU de Pointe a Pitre   (France)

^af NANTES UNIVERSITY HOSPITAL   (France)

^ag Unit for Basic and Clinical Research on Viral Hepatitis   (France)

^ah Clinical Trial Safety and Public Health   (France)

^ai HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

Chronic hepatitis C; Cirrhosis; Daclatasvir; Direct antiviral agents; Genotype 1; Hepather cohort; Severe fibrosis; Sofosbuvir; Treatment

Indexed keywords

ALBUMIN; DACLATASVIR; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BRADYCARDIA; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FEMALE; HEADACHE; HEART ATRIUM FLUTTER; HEART FAILURE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPTIC SHOCK; TREATMENT DURATION; AGED; CHRONIC HEPATITIS C; CLINICAL TRIAL; DRUG EFFECTS; FRANCE; GENETICS; HEPACIVIRUS; PROCEDURES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85000348640     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.021     Document Type: Article

References (31)

1. [1] Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465 (2010), 96–100.
2. [2] Fridell, R.A., Qiu, D., Wang, C., Valera, L., Gao, M., Resistance analysis of the hepatitis C virus NS5A inhibitor BS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54 (2010), 3641–3650.
3. [3] Sofia, M.J., Bao, D., Chang, W., Du, J., Nagarathnam, D., Rachakonda, S., et al. Discovery of a beta-d-2’-deoxy-2’-alfa-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53 (2010), 7202–7218.
4. [4] Bifano, M., Hwang, C., Oosterhuis, B., Hartstra, J., Grasela, D., Tiessen, R., et al. Assessment of pharcokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 18 (2013), 931–940.
5. [5] Bifano, M., Sevinsky, H., Hwang, C., Kandoussi, H., Jiang, H., Grasela, D., et al. Effect of coadministration of daclatasvir on the pharmacokinetics of combined oral contraceptive containing ethynil estradiol and norgestimate. Antivir Ther 19 (2014), 511–519.
6. [6] Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Eng J Med 368 (2013), 34–44.
7. [7] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Eng J Med 370 (2014), 211–221.
8. [8] Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanien, T., Gordon, S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Eng J Med 368 (2013), 1878–1887.
9. [9] Jacobson, I.L., Gordon, S.C., Kowdley, K.V., Yoshida, E.M., Rodriguez-Torres, M., Sulkowski, M.S., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Eng J Med 368 (2013), 1867–1877.
10. [10] Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Eng J Med 370 (2014), 1993–2001.
11. [11] Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N., et al. All-oral 12 week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
12. [12] Sulkowski, M.S., Naggie, S., Lalezari, J., Fessel, W.J., Mounzer, K., Shuhart, M., et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312 (2014), 353–361.
13. [13] Rockstroh, J.K., Puoti, M., Rodriguez-Torres, M., et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT 1–4 infection: the photon 1 and 2 trials. Hepatology, 60S, 2014, 87A(A195).
14. [14] Molina, J.M., Orkin, C., Iser, D.M., Zamora, F.X., Nelson, M., Stephan, C., et al. Sofosbuvir plus Ribavirin for treatment of hepatitis C virus in patients coinfected with HIV (PHOTON-2): a multicentre, open-label, non-randomised study. Lancet 385 (2015), 1098–1106.
15. [15] Wyles, D., Ruane, P., Sulkowski, M., Dieterich, D., Luetkemeyer, A., Morgan, F., et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Eng J Med 373 (2015), 714–725.
16. [16] Charlton, M., Gane, E., Manns, M.P., Brown, R.S. Jr, Curry, M.P., Kwo, P.Y., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
17. [17] AASLD HCV guidance: Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org.
18. [18] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. Available at: www.easl.eu/research/ow-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of hepatitis C, 2015.
19. [19] Chulanov, V., Zhdanov, K., Kersey, K., et al. Sofosbuvir plus ribavirin for the treatment of russian patients with chronic HCV genotype 1 or 3 infection. Hepatology, 60S, 2014, 134A(A982).
20. [20] Ruane, P.J., Ain, D., Stryker, R., Meshrekey, R., Soliman, M., Wolfe, P.R., et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C infection in patients of Egyptian ancestry. J Hepatol 62 (2015), 1040–1046.
21. [21] Doss, W., Shiha, G., Hassany, M., Soliman, R., Fouad, R., Khairy, M., et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis genotype 4. J Hepatol 63 (2015), 581–585.
22. [22] Höner Zu Siederdissen, C., Maasoumy, B., Deterding, K., Port, K., Sollik, L., Mix, C., et al. Eligibility and safety of the first IFN-free therapy against hepatitis C in a real-world setting. Liver Int 35 (2015), 1845–1852.
23. [23] Fontana, R.J., Hughes, E.A., Bifano, M., Appelman, H., Dimitrova, D., Hindes, R., et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 13 (2013), 1601–1605.
24. [24] Pellicelli, A.M., Montalbano, M., Lionetti, R., Durand, C., Ferenci, P., D'Offizi, G., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liv Dis 46 (2014), 923–927.
25. [25] Leroy, V., Dumortier, J., Coilly, A., Sebagh, M., Fougerou-Leurent, C., Radenne, et al. Efficacy of Sofosbuvir and Daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 13 (2015), 1993–2001.
26. [26] Dieterich, D., Bacon, B., Flamm, S., et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology, S60, 2014, 55A(A46).
27. [27] Reddy, J., Lim, J.K., Kuo, A., Di Bisceglie, A.M., Vargas, H.E., Galati, J.S., et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-Target real world experience. J Hepatol, S62, 2015, S183(A007).
28. [28] Saxena, V., Koraishy, F.M., Sise, M., Lim, J.K., Chung, R.T., Liapakis, A., et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-Target. J Hepatol, 62, 2015, S263(LP08).
29. [29] Bourlière, M., Bronowicki, J.P., de Ledinghen, V., Hezode, C., Zoulim, F., Mathurin, P., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15 (2015), 397–404.
30. [30] Younossi, Z.M., Stepanova, M., Pol, S., Bronowicki, J.P., Carrieri, M.P., Bourlière, M., The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int, 2015, 10.1111/liv.12886.
31. [31] Hézode, C., Chevaliez, S., Scoazec, G., Soulier, A., Varaut, A., Bouvier-Alias, M., et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology 63 (2016), 1809–1816.